a Unità Operativa Complessa di Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali (BIOMORF) , Università degli Studi di Messina , Messina , Italy.
b Centro Interdipartimentale per lo Studio delle Malattie Infiammatorie delle Vie Aeree e Patologie Fumo-correlate (CEMICEF; formerly Centro di Ricerca su Asma e BPCO), Sezione di Medicina Interna e Cardiorespiratoria , Università di Ferrara , Ferrara , Italy.
Expert Rev Respir Med. 2017 Dec;11(12):955-967. doi: 10.1080/17476348.2017.1386564. Epub 2017 Oct 6.
Current national and international guidelines for the management of patients with stable chronic obstructive pulmonary disease (COPD) recommend the use of inhaled long-acting bronchodilators, inhaled glucocorticoids and their combinations for maintenance treatment of moderate to severe stable COPD. Areas covered: The role of fluticasone furoate (FF) and vilanterol (VI) once daily combination therapy for the regular treatment of patients with stable COPD is discussed in this review. Expert commentary: The regular treatment of moderate to severe stable COPD with once daily FF/VI combination therapy is effective, as seen in in several large placebo-controlled clinical trials involving many thousands of patients. FF/VI improved lung function, decreased respiratory symptoms and decreased the number of COPD exacerbations, including COPD-related hospitalizations. FF/VI combination therapy has also been approved for this indication in most countries. The use of this combination therapy may significantly decrease the economic costs for some National Health Services.
目前，国内外管理稳定期慢性阻塞性肺疾病（COPD）患者的指南建议使用长效吸入支气管扩张剂、吸入糖皮质激素及其联合制剂进行中重度稳定期 COPD 的维持治疗。
本文讨论了氟替卡松糠酸酯（FF）和维兰特罗（VI）每日 1 次联合治疗方案在稳定期 COPD 患者常规治疗中的作用。
每日 1 次 FF/VI 联合治疗中重度稳定期 COPD 的疗效在几项涉及数千名患者的大型安慰剂对照临床试验中得到证实。FF/VI 改善了肺功能，减轻了呼吸道症状，减少了 COPD 恶化次数，包括与 COPD 相关的住院次数。FF/VI 联合治疗也已在大多数国家获得该适应证的批准。该联合治疗方案的使用可能会显著降低某些国家医疗服务的经济成本。
